Landfar(SZ:000504) Zheng Quan Shi Bao Wang·2025-08-11 13:56Group 1 - The core point of the article is that *ST Bio is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd., which will become a subsidiary after the transaction, indicating a significant asset restructuring [1] - Huize Biomedical is a specialized CRO company focused on drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services and established partnerships with over 300 pharmaceutical companies and research institutions [1] - The acquisition is expected to enhance *ST Bio's profitability and risk resistance by extending its biopharmaceutical business and improving operational efficiency through asset integration [1] Group 2 - The transaction is anticipated to strengthen the overall growth and profitability of *ST Bio, fostering core competitiveness in the new production capacity system and supporting long-term sustainable development [2] - Following the acquisition, *ST Bio's biopharmaceutical segment will include drug research and clinical evaluation services, which will enhance the company's competitive edge and align with shareholder interests [2] - *ST Bio previously forecasted a revenue of 49 million to 52 million yuan for the first half of 2025, representing a year-on-year decline of 7.68% to 13%, with a projected net loss of 3.5 million to 5 million yuan [2]